|
|
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
| |
X4 Pharmaceuticals Inc's Quick Ratio
XFOR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Current Liabilities decreased faster than X4 Pharmaceuticals Inc's Cash & cash equivalent, this led to improvement in X4 Pharmaceuticals Inc's Quick Ratio to 3.36, Quick Ratio remained below X4 Pharmaceuticals Inc average.
Within Biotechnology & Pharmaceuticals industry 69 other companies have achieved higher Quick Ratio than X4 Pharmaceuticals Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 718, from total ranking in the fourth quarter 2024 at 821.
Explain Quick Ratio?
How much Cash & cash equivalents XFOR´s has?
What are XFOR´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| XFOR Quick Ratio |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Current Liabilities Change |
15.51 % |
30.06 % |
32.85 % |
51.46 % |
6.07 % |
| Y / Y Cash & cash equivalent Change |
7.52 % |
-27.97 % |
-4.48 % |
80.67 % |
-33.56 % |
| Quick Ratio MRQ |
3.36 |
3.23 |
4.81 |
6.09 |
3.61 |
| XFOR's Total
Ranking |
# 718 |
# 821 |
# 627 |
# 528 |
# 828 |
| Seq. Current Liabilities Change |
-18.16 % |
12.8 % |
1.1 % |
23.75 % |
-7.85 % |
| Seq. Cash & cash equivalent Change |
-14.8 % |
-24.39 % |
-20.02 % |
108.68 % |
-42.92 % |
| Quick Ratio first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 70 |
| Healthcare Sector |
# 355 |
| Overall Market |
# 717 |
| Quick Ratio Statistics |
| High |
Average |
Low |
| 16.36 |
6.51 |
1.36 |
| (Mar 31 2020) |
|
(Mar 31 2019) |
Cumulative X4 Pharmaceuticals Inc's Quick Ratio
XFOR's Quick Ratio for the trailling 12 Months
XFOR Quick Ratio |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Current Liabilities TTM Growth |
31.51 % |
29.4 % |
16.35 % |
8.77 % |
3.28 % |
| Y / Y Cash & cash equivalent TTM Growth |
7.76 % |
-2.3 % |
20.63 % |
55.57 % |
44.99 % |
| Quick Ratio TTM |
4.35 |
4.43 |
5.13 |
5.57 |
5.31 |
| Total Ranking TTM |
# 2393
| # 3083
| # 3114
| # 2372
| # 2157
|
| Seq. Current Liabilities TTM Growth |
3.17 % |
7.13 % |
7.26 % |
10.94 % |
1.51 % |
| Seq. Cash & cash equivalent TTM Growth |
1.25 % |
-7.53 % |
-1.19 % |
16.48 % |
-8.2 % |
On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2025 to $25.88 millions, cumulative Quick Ratio decreased to 4.35 below the X4 Pharmaceuticals Inc average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Biotechnology & Pharmaceuticals industry 116 other companies have achieved higher Quick Ratio than X4 Pharmaceuticals Inc. While Quick Ratio overall ranking has improved so far to 2393, from total ranking during the twelve months ending fourth quarter 2024 at 3083.
Explain Quick Ratio?
How much Cash & cash equivalents XFOR´s has?
What are XFOR´s Current Liabilities?
| TTM Quick Ratio Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# 117 |
| Healthcare Sector |
# 689 |
| Within the Market |
# 2393 |
| trailing twelve months Quick Ratio Statistics |
| High |
Average |
Low |
| 11.55 |
5.98 |
3.46 |
| (Jun 30 2020) |
|
(Sep 30 2022) |
|
Date modified: 2025-05-23T09:22:02+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
